Today wasn’t a great day for most ASX shares. The All Ordinaries Index (ASX: XAO) ended up losing 0.93% over this Tuesday’s trading session. But that loss was eclipsed by the Race Oncology Ltd (ASX: RAC) share price.
Race shares ended up finishing at $2.30 a share, down a nasty 9.8% for the day. What’s worse, the company hit $2.27 during intra-day trading a new 52-week low for Race Oncology. That puts the company’s losses over 2022 so far at 36%, including 17.3% over the past 5 trading days. Its 12-month loss now stands at 38%.
So why did this company have such a lousy day of trading today?
Race to the bottom for Race Oncology share price
Well, unfortunately, it’s not entirely clear. There were no announcements or news out of the company to speak of. Nor have there been since a major update in January, which was an activities update for the December quarter. Back then, the company announced that its capital raising had been successful and oversubscribed at $3 a share. Race also reported a healthy cash position as well as a “preclinical discovery into heart protection during cancer treatment”.
That caused the Race share price to rise at the time. But investors appear to have forgotten all about those developments today.
So while it’s unclear exactly what spooked investors today, it could just be the nature of the company itself. As a small-cap ASX share with a market capitalisation of just over $400 million, Race is a company that could have been treated as a more speculative investment by some of its shareholders. As such, on a day like today when investors didn’t seem in the mood to take risks, Race shares might have just been the victim of some fear-provoked selling pressure.
Whatever the reasons for today’s sell off, Race shareholders will undoubtedly be hoping for better fortunes over the rest of the week.
The post Why did the Race Oncology (ASX:RAC) share price drop 10% today? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Race Oncology right now?
Before you consider Race Oncology, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Race Oncology wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- Black gold! 3 ASX energy shares pumping new 52-week highs today
- Ups and downs: Why is the Cettire share price leaping 10% today?
- The Cettire (ASX:CTT) share price is plunging 14% today. What’s going on?
- Hazer (ASX:HZR) share price rockets 14% on low-carbon hydrogen project
- Selling out? Cettire (ASX:CTT) share price slumps amid founder selling rumours
Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/kp0szt1
Stock Pick 